Supplemental Figure 1: Patient disposition

Enrolled
N=666 (100.0%)

- Consent withdrawn, n=1 (0.2%)

- gBRCA mutation test performed
  n=665 (99.8%)

  - Withdrawn, n=2 (0.3%)
    - Consent withdrawn n=1 (0.2%)
    - Other n=1 (0.2%)

- Full analysis set
  (on the basis of centralized pathological results)
  n=634 (95.2%)

- Excluded from full analysis set
  (on the basis of centralized pathological results)
  n=29 (4.4%)

gBRCA, germline BRCA
Supplemental Figure 2: Prevalence of gBRCA mutations in the study population by age

gBRCA, germline BRCA
Supplemental Figure 3: Prevalence of gBRCA mutations by cancer diagnosis (attending physician)

Epithelial ovarian cancer
- gBRCA1: 3.9%
- gBRCA2: 8.8%
- Mutations absent: 4.9%
- Variant of uncertain significance: 82.4%

Primary peritoneal cancer
- gBRCA1: 3.8%
- gBRCA2: 17.3%
- Mutations absent: 1.9%
- Variant of uncertain significance: 76.9%

Fallopian tube cancer
- gBRCA1: 14.6%
- gBRCA2: 14.6%
- Mutations absent: 4.2%
- Variant of uncertain significance: 66.7%

gBRCA, germline BRCA
Supplemental Figure 4: Age distribution by carcinoma type

Epithelial ovarian cancer
- 20–29: 10.7%
- 30–39: 25.1%
- 40–49: 30.9%
- 50–59: 24.7%
- 60–69: 0.7%
- 70–79: 0.7%
- ≥80: 0.7%

Primary peritoneal cancer
- 20–29: 5.8%
- 30–39: 44.2%
- 40–49: 19.2%
- 50–59: 23.1%
- 60–69: 14.6%
- 70–79: 2.1%
- ≥80: 14.6%

Fallopian tube cancer
- 20–29: 14.6%
- 30–39: 16.7%
- 40–49: 52.1%
- 50–59: 5.8%
- 60–69: 2.1%
- 70–79: 14.6%
- ≥80: 0.7%
Supplemental Figure 5: FIGO stage distribution by carcinoma type

Epithelial ovarian cancer

- Stage I: 41.4%
- Stage II: 35.2%
- Stage III: 11.4%
- Stage IV: 11.6%
- Other: 0.4%
- Total: 534

Primary peritoneal cancer

- Stage I: 65.4%
- Stage II: 3.8%
- Stage III: 3.8%
- Stage IV: 1.9%
- Other: 12.5%
- Total: 52

Fallopian tube cancer

- Stage I: 45.8%
- Stage II: 14.6%
- Stage III: 27.1%
- Stage IV: 12.5%
- Other: 0.0%
- Total: 48

FIGO, International Federation of Gynecology and Obstetrics
Supplemental Figure 6: Histological subtype by FIGO stage

Stage I/II

- Low-grade serous: 45.3%
- High-grade serous: 30.6%
- Mucinous: 14.7%
- Endometrioid: 5.2%
- Clear cell: 0.7%
- Other: 0.9%

Stage III/IV

- Low-grade serous: 69.8%
- High-grade serous: 14.8%
- Mucinous: 8.0%
- Endometrioid: 5.6%
- Clear cell: 0.9%
- Other: 0.9%

FIGO, International Federation of Gynecology and Obstetrics